An Overview of Clinical Xenotransplantation Regulatory Issues

• Published in: International journal of organ transplantation medicine 2022-07, Vol.13 (3), p.40-53
• Main Authors: Gaganashree, T V, Venkatesh, M P, Balamuralidhara, V, Gowrav, M P
• Format: Article
• Language: English
• Subjects: Animals; Blood & organ donations; Blood transfusions; Clinical trials; Eggs; Genetic engineering; Health services; Medical waiting lists; Patients; Public health; Skin; Transplants & implants; Uterus; Xenotransplantation
• ISSN: 2008-6482; 2008-6490

Any technique that includes the transplantation, implantation, or infusion into a human recipient of either [1]: * Living tissues, cells, or organs derived from non-human animals. * Bodily fluids, cells, tissues, or organs from living non-human animals that have had in ex vivo contact with human cells, tissues, as well as organs is how the World Health Organization (WHO) characterises xenotransplantation. Because it brings up all the complex bioethical concerns in one scenario, xenotransplantation is a fascinating topic in applied ethics. According to the US Public Health Service definition, the multicellular stage fertilisation product that was transplanted into the mother's uterus and eventually gave rise to the child was a xenotransplantation product. Advancement of Porcine to Human Organ Xenotransplantation * The global market for organ and tissue transplantation items and technologies was $59,6 billion in 2014, with a projected increase to $90 billion by 2020. * There is a significant lack of acceptable human organs for clinical transplantation, which is driving an increase in demand for synthetic and/or xenogeneic organs. * Intrexon's integrated technologies and patented platforms, including its genetically diversified lone star Yucatan miniswine families, provide end-to-end solutions for cell and orange engineering for xenotransplantation [4] (Fig 2). [...]human blood transfusion and xenotransplantation both originated from xenotransfusion.